The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Peptide Therapy Beverly Hills Tissue & Gut Repair BPC 157: The peptide with big claims and scant evidence STAT Hims & Hers stock rises as FDA schedules peptide review The FDA just announced a July advisory panel to review BPC 157, TB 500, and 5 more restricted peptides for legal compounding access. Full breakdown at the link in bio peptideacademy.io blog #peptides #BPC157 #